Summaries of safety labeling changes approved by FDA—Boxed warnings highlights, July–September 2022.

The article presents summaries of safety labeling changes approved by the U.S. Food and Drug Administration (FDA) from July to September 2022. These include the additions and revisions to the labeling of Arthrotec (diclofenac sodium/misoprostol), opzelura (ruxolinitib phosphate), and ultomiris (ravulizumab-cwvz).